		TRANSMITTAL LETTER		Case No. 10716-12/Cura-104
Serial No. 09/715,478	Filing Date November 16, 2000	Examiner To Be Assigned		Group Art Unit
Inventor Luca Rastelli et al.				
Title of Invention WNT-REGULATED CYTOKINE-LIKE POLYPEPTIDE AND NUCLEIC ACIDS ENCODING SAME				

TO THE COMMISSIONER FOR PATENTS


Transmitted herewith is Transmittal Letter (in Duplicate); Information Disclosure Statement, PTO Form 1449; copies of cited references A1-A20.

- ☐ Small entity status of this application under 37 CFR § 1.27 has been established by verified statement previously submitted.
- ☐ A verified statement to establish small entity status under 37 CFR §§ 1.9 and 1.27 is enclosed.
- ☐ Petition for a _____ month extension of time.
- ☒ No additional fee is required.
- ☐ The fee has been calculated as shown below:

					Small Entity		Other Than Small Entity	
	Claims Remaining After Amendment		Highest No. Previously Paid For	Present Extra	Rate	Add'l Fee	Rate	Add'l Fee
Total		Minus			x \$9=		x \$18=	
Indep.		Minus			x 39=		x \$78=	
First Presentation of Multiple Dep. Claim					+\$130 =		+ \$260=	
					Total add'l fee	\$	total add'l fee	\$

- ☐ Please charge Deposit Account No. 23-1925 (BRINKS HOFER GILSON & LIONE) in the amount of \$_____. A duplicate copy of this sheet is enclosed.
- ☐ A check in the amount of \$_____ to cover the filing fee is enclosed.
- ☒ The Commissioner is hereby authorized to charge payment of any additional filing fees required under 37 CFR § 1.16 and any patent application processing fees under 37 CFR § 1.17 associated with this communication or credit any overpayment to Deposit Account No. 23-1925. A duplicate copy of this sheet is enclosed.
- ☒ I hereby petition under 37 CFR § 1.136(a) for any extension of time required to ensure that this paper is timely filed. Please charge any associated fees which have not otherwise been paid to Deposit Account No. 23-1925. A duplicate copy of this sheet is enclosed.


Respectfully submitted,


 Paul E. Rauch, Ph.D.
 Registration No. 38,591
 Attorney for Applicants

BRINKS HOFER GILSON & LIONE
 P.O. BOX 10395
 CHICAGO, ILLINOIS 60610 - (312) 321-4200

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, with sufficient postage, in an envelope addressed to:
 Commissioner for Patents, Washington, D.C. 20231, on March 13, 2001.

Date: 3/13/01
 rev. Dec.-99

Signature: 



CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope, with sufficient postage, addressed to:
Commissioner for Patents, Washington, D.C. 20231, on

3/13/01

Date of Deposit

Paul E. Rauch, Ph. D., Reg. No. 38,591

Name of Applicant, Assignee or
Registered Representative

Paul E. Rauch

Signature

3/13/01

Date of Signature

Our Case No.: 10716-12/Cura-104

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Luca Rastelli et al.

Serial No.: 09/715,418

Filing Date: November 16, 2000

For: WNT-REGULATED CYTOKINE-LIKE
POLYPEPTIDE AND NUCLEIC ACIDS
ENCODING SAME

Examiner: To Be Assigned

Group Art Unit No.:

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed below and on the attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

The references now cited are the following:

U.S. PATENT DOCUMENT

DOCUMENT NUMBER	DATE	NAME
5,871,697	2/16/99	Rothberg et al.

FOREIGN PATENT DOCUMENT

DOCUMENT NUMBER	DATE	COUNTRY
WO 97/34013	9/18/97	PCT

OTHER ART (including Author, Title, Date, Pertinent Pages, etc.)

Camby, I., F. Lefranc, et al., "Differential expression of S100 calcium-binding proteins characterizes distinct clinical entities in both WHO grade II and III astrocytic tumours", <i>Neuropathology and Applied Neurobiology</i> , 26 (2000), pp 76-90.
Dale, I., M. K. Fagerhol, et al., "Purification and partial characterization of a highly immunogenic human leukocyte protein, the L1 antigen", <i>Euro J Biochem</i> 134 (1983), pp 1-6.
De Ferrari, G. V. and N. C. Inestrosa, "Wnt signaling function in Alzheimer's disease", <i>Brain Research Reviews</i> 33 (2000), pp 1-12.
Djukanovic, D., U. Hofmann, et al., "Comparison of S100 protein and MIA protein as serum marker for malignant melanoma", <i>Anticancer Research</i> , 20 (2000), pp 2203-2208.
Donato, R., "Functional roles of S100 proteins, calcium-binding proteins of the EF- hand type." <i>Biochimica et Biophysica Acta</i> 1450 (1999), pp 191-231.
Huang, X., "A contig assembly program based on sensitive detection of fragment overlaps" <i>Genomics</i> 14 (1992), pp 18-25.
Kerlavage, A.R., Direct Submission. GenBank Accession Number: AA315020 , 1997, pp 1-2
Kligman, D. and D. C. Hilt, "The S100 protein family", <i>Trends Biochemistry Science</i> 13 (1988), pp 437-443.
Kuhl, M., L. C. Sheldahl, et al., "The Wnt/Ca ²⁺ pathway: a new vertebrate Wnt signaling pathway takes shape", <i>Trends Genet</i> 16 (2000), pp 279-283.
Nacken, W., C. Sopalla, et al., "Biochemical characterization of the murine S100A9 (MRP14) protein suggests that it is functionally equivalent to its human counterpart despite its low degree of sequence homology", <i>Eur J Biochem</i> 267 (2000), pp 560-565.
Patapoutian, A. and L. F. Reichardt, "Roles of Wnt proteins in neural development and maintenance" <i>Curr Opin Neurobiol</i> 10 (2000), pp 392-399.
Peifer, M. and P. Polakis, "Wnt signaling in oncogenesis and embryogenesis--a look outside the nucleus", <i>Science</i> 287(2000), pp 1606-1609.
Pietas, et al., "Human cDNA of a new member of the s100 protein family which is downregulated in lung carcinoma cells" Direct Submission. GenBank Accession Number: AY007220 , 2000, pp 1-2.
Sastry, M., R. R. Ketchum, et al., "The three-dimensional structure of Ca(2+)-bound calcyclin: implications for Ca(2+)-signal transduction by S100 proteins", <i>Structure</i> 6 (1998), pp 223-231.
Sheng, J. G., R. E. Mrak, et al., "Overexpression of the neuritotropic cytokine S100beta precedes the appearance of neuritic beta-amyloid plaques in APPV717F mice" <i>J Neurochem</i> 74 (2000), pp 295-301.
Shimkets, R. A., D. G. Lowe, et al., "Gene expression analysis by transcript profiling coupled to a gene database query", <i>Nature Biotechnology</i> 17 (1999), pp 798-803.

Smalley, M. J. and T. C. Dale, "Wnt signalling in mammalian development and cancer" Cancer Metastasis Rev 18 (1999), pp 1-2. (ABSTRACT ONLY)

Xu, K. and C. L. Geczy, "IFN-gamma and TNF regulate macrophage expression of the chemotactic S100 protein S100A8", The Journal of Immunology 164 (2000), pp 4916-4923.

In accordance with 37 C.F.R. § 1.97(g),(h), this information Disclosure Statement is not to be construed as a representation that a search has been made and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

This Information Disclosure Statement is being filed prior to the receipt of the first Official Action reflecting an examination on the merits and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these material, the Commissioner is hereby authorized to deduct said fees from Brinks Hofer Gilson & Lione Deposit Account No. 23-1925.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,



Paul E. Rauch, Ph. D.
Registration No. 38,591
Attorney for Applicants

BRINKS HOFER GILSON & LIONE
P.O. Box 10395
Chicago, IL 60610
(312) 321-4200